Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas — Stella
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(14 sites)
France
CHU Amiens, Amiens
Institut Sainte Catherine, Avignon
Chu Bordeaux - Hopital Saint André, Bordeaux
Centre Jean Perrin, Clermont-Ferrand
Centre Oscar Lambret, Lille
Chu Limoges, Limoges
Centre Hospitalier Regional de Marseille, Marseille